Effect of growth hormone (GH) during puberty in GH‐deficient children: preliminary results from an ongoing randomized trial with different dose regimens
- 1 February 1999
- journal article
- clinical trial
- Published by Wiley in Acta Paediatrica
- Vol. 88 (s428) , 80-84
- https://doi.org/10.1111/j.1651-2227.1999.tb14358.x
Abstract
Albertsson Wikland K, Alm F, Aronsson S, Gustafsson J, Hagenas L, Hager A, Ivarsson S, Kristrom B, Marcus C, Moe11 C, Nilsson KO, RitzCn M, Tuvemo T, Westgren U, Westphal 0, Aman J. Effect of growth hormone (GH) during puberty in GH‐deficient children: preliminary results from an ongoing randomized trial with different dose regimens. Acta Pxdiatr 1999; Suppl 428:80‐4. Stockholm. ISSN 0803‐5326 This paper reports results from an ongoing, randomized, multicentre national trial. The aim is to elucidate whether a dose of growth hormone (GH) of 0.2 IUkg (0.07 mgkg), given either as once‐daily or twice‐daily injections during puberty, is more effective than a once‐daily dose of 0.1 IU/kg/day (0.03 mg/kg/day) in improving final height in children with GH deficiency (GHD). The twice‐daily regimen comes closer to the spontaneous GH secretion pattern in puberty. Ninety‐two children with GHD who had been receiving GH therapy for at least 1 year, and with spontaneous puberty or who were prepubertal and due to be started on replacement therapy to induce puberty, were randomly assigned to receive GH as follows: group A, 0.1 IU/kg/day (0.03 mg/kg/day), administered once daily; group B, 0.2 IU/kg/day (0.07 mg/kg/day), administered once daily; and group C, 0.2 IUkg/day (0.07 mg/kg/day), divided into two equal injections given at 12‐hour intervals. Pubertal height gain was 0.7, 0.7 and 1.3 SDS for groups A, B and C, respectively. The gain in height during puberty was thus most marked in group C. Mean final height, when corrected for parental height, was between 0 and 1 SDS in all treatment groups. All but seven children reached a final height within 2 SD of the general population. There was a wide range of final heights in all three treatment groups. This variation in response suggests the need to individualize treatment in order to achieve an appropriate final height for most individuals. □Dose, final height, growth hormone treatment, puberty, randomized treatment trialKeywords
This publication has 20 references indexed in Scilit:
- Growth Response to Growth Hormone (GH) Treatment Relates to Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Short Children with Various GH Secretion CapacitiesJournal of Clinical Endocrinology & Metabolism, 1997
- Adult Height in Growth Hormone (GH)-Deficient Children Treated with Biosynthetic GHJournal of Clinical Endocrinology & Metabolism, 1997
- Is Growth Hormone Deficiency a Viable Diagnosis?Journal of Clinical Endocrinology & Metabolism, 1997
- Prediction of the outcome of growth hormone therapy in children with idiopathic short stature: A multivariate discriminant analyisThe Journal of Pediatrics, 1995
- Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisitedJournal of Clinical Endocrinology & Metabolism, 1995
- Prediction of the growth response of short prepubertal children treated with growth hormoneActa Paediatrica, 1995
- Prediction of the growth response in children with various growth disorders treated with growth hormone: analyses of data from the Kabi Pharmacia International Growth StudyActa Paediatrica, 1993
- Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiencyJournal of Clinical Endocrinology & Metabolism, 1993
- Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.Archives of Disease in Childhood, 1976